Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4233307 | 0.88 | EPHX2 (0.50) | EPHX2HRH3GPR119 | |
| SCHEMBL2237539 | 0.85 | HRH3 (0.56) | ACACBHRH3 | |
| Trifluoroacetic Acid SCHEMBL23830454 | 0.84 | SLC6A4 (0.51) | EPHX2 | |
| Hydrochloric Acid SCHEMBL2991787 | 0.83 | HRH3 (0.54) | ACACBHRH3 | |
| Trifluoroacetic Acid SCHEMBL20958376 | 0.83 | SLC6A4 (0.55) | EPHX2HRH3GPR119 | |
| Trifluoroacetic Acid SCHEMBL20958496 | 0.83 | SLC6A4 (0.55) | EPHX2HRH3GPR119 | |
| Trifluoroacetic Acid SCHEMBL23830859 | 0.82 | SLC6A2 (0.45) | — | |
| Trifluoroacetic Acid SCHEMBL30182604 | 0.82 | ITGB1 (0.41) | — | |
| Trifluoroacetic Acid SCHEMBL23830576 | 0.82 | MGLL (0.40) | — | |
| Trifluoroacetic Acid SCHEMBL23830840 | 0.81 | SLC6A2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120058698-A | Azetidine and pyrrolidine PARP1 inhibitors and uses thereof | 新特拉有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-118019532-B | Azetidine and pyrrolidine PARP1 inhibitors and uses thereof | 新特拉有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-118019532-A | Azetidine and pyrrolidine PARP1 inhibitors and uses thereof | 新特拉有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-20210292305-A1 | Cyclic Ureas | SIRONAX LTD (KY) | 2021-09-23 | — | — | US | disclosed |
| CN-113302183-A | Cyclic ureas | 圣瑞诺有限公司 | 2021-08-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292305-A1 | Cyclic Ureas | RIPK1, RIPK3, RIPK4 | EPHX2 3955/4885ACACB 4600/4885HRH3 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.